secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2026-09-18T12:23:28+00:00
Accession:  0001159036-26-000126
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme prices $1.3B convertible senior notes due 2033 at 1.50%; upsized from $1.05B
--------------------------------------------------------------------------------

- $1.3B aggregate principal of 1.50% convertible notes due Oct 1, 2033, upsized from $1.05B; 13-day greenshoe for up to $200M.
- Initial conversion price ~$139.84/share (27.5% premium above $109.68 close); cap price of capped calls ~$208.39/share.
- Net proceeds ~$1.275B; ~$162.5M funds capped calls, remainder for note repurchases, working capital, acquisitions.
- To repurchase ~$151.7M of 0.25% 2027 notes (cost ~$217.0M) and $220.0M of 1.00% 2028 notes (cost ~$435.5M).
- Closing expected Sept 22, 2026; offering private to QIBs under Rule 144A; settle conversions in cash plus shares if applicable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000126/0001159036-26-000126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000126/halo-20260917.htm
  HTML page:      https://secwatch.observer/filing/0001159036-26-000126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer